RxDoctor Payments Data

Michael Schneck, MD

Vascular Neurology · Maywood, ILNPI 1023086642

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Penumbra, Inc. at 44.0% of the total. 2025 is the largest year on record at $164, 3.2 times the $52 reported in 2019. That places this record below the midpoint for vascular neurology clinicians in IL, where the typical reported total is $1,573.

$269in general payments, 2019–2025

Across 6 payments — averaging $44.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$119
  • Chiesi USA, Inc.$52
  • TG Therapeutics, Inc.$45
  • Novartis$28
  • Bayer$13
  • Amgen$13
$41,620in research payments, 2019–2025

Across 6 payments — averaging $6936.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$31K
  • Dova Pharmaceuticals$10K
  • W. L. Gore & Associates, Inc.$756

What the payments were for

  • Food & beverage$269100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$269 in reported general payments places this provider in the 35th percentile of 32 vascular neurology providers in Illinois.

See all vascular neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$160,129
Medicare patients
606
Services billed
1,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab35$27,983
EliquisApixaban29$27,480
Nurtec OdtRimegepant Sulfate12$19,313
Emgality PenGalcanezumab-Gnlm17$13,490
Lacosamide33$2,625
Oxcarbazepine24$1,775
Levetiracetam44$1,461
Gabapentin71$1,357
Pregabalin47$1,240
Primidone11$1,207
Memantine Hcl49$791
Baclofen32$686
ClopidogrelClopidogrel Bisulfate38$543
Ezetimibe20$410
Duloxetine Hcl23$400

Paid to pharmacies, not to this prescriber.

Other vascular neurology in Maywood

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →